- Autoantibody biomarkers can be used to establish signatures for predicting if patients are likely to respond to treatment.
- These predictive signatures can also be used to identify patient populations likely to experience adverse events.
- Having the ability to interrogate hundreds of autoantibody targets in a single assay can help accelerate the identification and validation of signatures with high predictive value.
Accelerating discovery of autoantibody signatures.
Sengenics can help, with solutions to support discovery of biomarker signatures. Our high-density protein microarray assays enable highly specific and reproducible detection of disease-relevant autoantibodies directly from patient serum.
Candidate Autoantibody Biomarkers for Anti-drug Antibodies in RA Patients